Docoh
Loading...

ABOS Acumen Pharmaceuticals

Acumen, headquartered in Charlottesville, VA with clinical operations based in Carmel, IN, is a clinical stage biopharmaceutical company developing a novel disease-modifying approach to treat Alzheimer’s disease. Acumen’s scientific founders pioneered research on AßOs, which a growing body of evidence indicates are primary triggers of Alzheimer’s disease pathology. Acumen is currently focused on advancing its investigational drug, ACU193, a humanized monoclonal antibody that selectively targets toxic AßOs, in a Phase I clinical trial involving early Alzheimer’s disease patients. We believe that ACU193 represents a differentiated approach from current and prior AD immunotherapies because it is highly selective for toxic AßOs and because it is engineered to reduce immune signaling. As such, ACU193 is expected to carry a reduced rate of amyloid-related imaging abnormalities, or ARIA, a common, dose-limiting adverse event observed with amyloid plaque-targeting immunotherapies.

ABOS stock data

(
)

Investment data

Data from SEC filings
Securities sold
Number of investors

Calendar

16 Aug 21
17 Oct 21
31 Dec 21
Quarter (USD)
Jun 21
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Financial data from company earnings reports.

Cash burn rate (estimated) Burn method: Change in cash Burn method: Operating income/loss Burn method: FCF (opex + capex)
Cash on hand (at last report) 68.81M
Cash burn (monthly) 1.15M
Cash used (since last report) 4.12M
Cash remaining 64.7M
Runway (months of cash) 56.4

Beta Read what these cash burn values mean

Date Owner Security Transaction Code Indirect 10b5-1 $Price #Shares $Value #Remaining
6 Jul 21 Ra Capital Management Common Stock Conversion Acquire C Yes No 0 588,850 0 588,850
6 Jul 21 Ra Capital Management Common Stock Buy Acquire P Yes No 16 115,668 1.85M 1,300,034
6 Jul 21 Ra Capital Management Common Stock Conversion Acquire C Yes No 0 1,184,366 0 1,184,336
6 Jul 21 Ra Capital Management Common Stock Buy Acquire P Yes No 16 1,759,332 28.15M 7,881,889
6 Jul 21 Ra Capital Management Common Stock Conversion Acquire C Yes No 0 6,122,557 0 6,122,557
6 Jul 21 Ra Capital Management Series B Preferred Stock Common Stock Conversion Dispose C Yes No 0 588,850 0 0
6 Jul 21 Ra Capital Management Series B Preferred Stock Common Stock Conversion Dispose C Yes No 0 1,184,366 0 0
6 Jul 21 Ra Capital Management Series B Preferred Stock Common Stock Conversion Dispose C Yes No 0 6,122,557 0 0
6 Jul 21 Sands Capital Ventures Discovery Fund III Common Stock Buy Acquire P No No 14.88 450,000 6.7M 3,417,075
6 Jul 21 Sands Capital Ventures Discovery Fund III Common Stock Conversion Acquire C No No 0 1,842,346 0 2,967,075

Data for the last complete 13F reporting period. To see the most recent changes to ownership, click the ownership history button above.

13F holders
Current Prev Q Change
Total holders 0 0
Opened positions 0 0
Closed positions 0 0
Increased positions 0 0
Reduced positions 0 0
13F shares
Current Prev Q Change
Total value 0 0
Total shares 0 0
Total puts 0 0
Total calls 0 0
Total put/call ratio
Largest owners
Shares Value Change
Largest transactions
Shares Bought/sold Change
Content analysis
?
Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability
H.S. sophomore Avg

Proxies

No filings